4-[2-ヒドロキシ-3-(イソプロピルアミノ)プロポキシ]ベンゼンプロパン酸メチル 化学特性,用途語,生産方法
使用
Esmolol is a cardioselective beta1 receptor blocking agent.
危険性
A reproductive hazard.
臨床応用
Esmolol (Brevibloc) is a short-acting intravenously administered
β1-selective adrenoceptor blocking agent. It
does not possess membrane-stabilizing activity or sympathomimetic
activity.
Esmolol is used in the treatment of supraventricular
tachyarrhythmias for rapid control of ventricular rate
and reduction of myocardial oxygen consumption.
Discontinuation of administration is followed by a rapid
reversal of its pharmacological effects because of esmolol’s
rapid hydrolysis by plasma esterases.
副作用
The most frequently reported adverse effects are hypotension,
nausea, dizziness, headache, and dyspnea.As
with many β-blocking drugs, esmolol is contraindicated
in patients with overt heart failure and those in cardiogenic
shock.
代謝
The -blocker esmolol (Brevibloc) is unusual in that
it is very rapidly metabolized; its plasma half-life is only
9 minutes. It is subject to hydrolysis by cytosolic esterases
in red blood cells to yield methanol and an acid
metabolite, the latter having an elimination half-life of
about 4 hours. Only 2% of the administered esmolol is
excreted unchanged. Because of its rapid onset and short duration of action, esmolol is used by the intravenous
route for the control of ventricular arrhythmias
in emergencies.
4-[2-ヒドロキシ-3-(イソプロピルアミノ)プロポキシ]ベンゼンプロパン酸メチル 上流と下流の製品情報
原材料
準備製品